Editor's Note: This Manuscript was accepted for publication January 3, 2008.
Developing a Rabbit Model of Rhinogenic Chronic Rhinosinusitis†
Article first published online: 2 JAN 2009
Copyright © 2008 The Triological Society
Volume 118, Issue 6, pages 1076–1081, June 2008
How to Cite
Liang, K.-L., Jiang, R.-S., Wang, J., Shiao, J.-Y., Su, M.-C., Hsin, C.-H. and Lin, J.-F. (2008), Developing a Rabbit Model of Rhinogenic Chronic Rhinosinusitis. The Laryngoscope, 118: 1076–1081. doi: 10.1097/MLG.0b013e3181671b74
- Issue published online: 2 JAN 2009
- Article first published online: 2 JAN 2009
- chronic disease;
- computed tomography;
- disease model;
- experimental study;
Objective: The purpose of this study was to develop a rabbit model of rhinogenic chronic rhinosinusitis (CRS).
Methods: New Zealand white rabbits were used and divided into two groups. In group A rabbits, a piece of Merocel (Medtronic-Xomed, Jacksonville, FL) was inserted into one nasal cavity and the other was left undisturbed as control. In group B rabbits, 1 μg phorbol 12-myristate 13-acetate (PMA) was injected into bilateral nasal lateral walls and then a piece of Merocel (Medtronic-Xomed) was inserted into one nasal cavity. At week 2, the Merocel (Medtronic-Xomed) was removed, and computed tomography (CT), nasoendoscopy, and cultures were performed. All examinations were repeated at week 12. Rabbits that had purulent discharge in nasal cavities and sinuses opacification shown in CT scans were diagnosed as having rhinosinusitis. Rabbits with CRS were randomly allocated to receive intravenous ceftriaxone (50 mg/kg/day) for 28 days or nothing. All rabbits with CRS received CT scans, nasoendoscopy, and cultures at week 16.
Results: At week 12, CRS had developed in two controlled nasal cavities, six nasal cavities inserted with Merocel (Medtronic-Xomed), six nasal cavities injected with phorbol 12-myristate 13-acetate (PMA), and seven both PMA-injected and Merocel- (Medtronic-Xomed) inserted nasal cavities. Seven of nine treated CRS sides were clear of opacification after treatment. All non-treated CRS sides had persistent diseases at week 16. There was a significant difference in the CRS incidence (P = .00043) and culture rates (P = .027) between treated and non-treated CRS nasal cavities.
Conclusions: Our study developed a rabbit model of rhinogenic CRS. This model is easily performed and is reversible by treatment.